Actively Recruiting
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Led by Swiss Cancer Institute · Updated on 2026-04-02
128
Participants Needed
7
Research Sites
218 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treated by surgery and/or radiation.
CONDITIONS
Official Title
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed tissue diagnosis of clinical stage IV non-small cell lung cancer
- ECOG performance status of 0 or 1
- Response after 3 cycles (or up to 4th bridging cycle) of first-line standard systemic therapy with partial response or stable disease
- Maximum of 5 residual extracranial distant metastases (oligometastatic or oligopersistent NSCLC)
- Up to 5 brain metastases allowed if treatable by surgery or radiotherapy
- Primary tumor and all metastases suitable for radical local ablative therapy (surgery or radiotherapy)
- Patients of reproductive age agree to use double contraception
- Ability to understand and comply with trial procedures with signed consent
You will not qualify if you...
- Serious medical conditions that increase risk during local ablative therapy
- Unresolved complications from initial systemic cancer treatment above CTCAE grade 2
- Metastases in locations such as malignant ascites, pleural or pericardial effusion, diffuse skin or lung lymphangiosis, diffuse bone marrow metastasis, or abdominal masses/organs detected by exam but not measurable by imaging
- Leptomeningeal carcinomatosis
- Pregnant or breastfeeding women
- Current participation in another clinical trial that prohibits or would overly burden participation in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Kantonspital Aarau
Aarau, Switzerland, 5001
Actively Recruiting
2
IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, Switzerland, 6500
Actively Recruiting
3
Kantonsspital Graubuenden
Chur, Switzerland, CH-7000
Actively Recruiting
4
Hôpital Fribourgeois - Hôpital Cantonal
Fribourg, Switzerland
Actively Recruiting
5
Hôpitaux Universitaires Genève HUG
Geneva, Switzerland, 1205
Actively Recruiting
6
Luzerner Kantonsspital
Lucerne, Switzerland
Actively Recruiting
7
Universitätsspital Zürich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
G
Gwendoline Wicki
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here